#ScienceLink #Madrid2026 #ESMO26 #HBI8000303 #HBI8000 #Nivolumab
En HBI-8000-303 (fase III; n=404), HBI-8000, inhibidor oral de HDAC, + nivolumab mejoró la SLP frente a placebo + nivolumab en melanoma no uveal irresecable o metastásico sin exposición previa a anti-PD-(L)1.
⏰ Mediana de seguimiento: 37 meses
⏳ SLP: 11.7 vs 7.4 meses (HR 0.73; IC 96%: 0.56–0.95; p=0.0141)
🎯 TRO: 41.4% vs 32.3% (p=0.0569; diferencia no significativa)
📊 SG aún inmadura
⚠️ EA relacionados con el tratamiento grado 3–4: 54.8% vs 17.9%. Suspensión definitiva por EA relacionados: 14.1% vs 5.0%.
🔗 Leer/escuchar noticia completa: https://buff.ly/e2X5xs8
69 浏览 · 0 赞 · 0 转发 · 0 回复
Emotional distress (ED) upfront neoadjuvant ipilimumab + nivolumab (IPI+NIVO) is associated with lower pathological response and toxicity
https://esmocongress.esmo.orgResults from a phase 3 trial of neoadjuvant (neoadj) chemotherapy alone vs in combination with nivolumab followed by postsurgical adjuvant nivolumab in patients (pts) with muscle-invasive bladder cancer (MIBC)
https://esmocongress.esmo.orgFinal pathological and radiological outcomes and initial EFS from a blinded, exploratory phase 2 trial of nivolumab ± visugromab in MIBC (GDFather-NEO)
https://esmocongress.esmo.orgPrimary analysis of HBI-8000-303: A randomized phase 3 trial of nivolumab plus HBI-8000 or placebo in advanced melanoma
https://esmocongress.esmo.org- **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)
https://esmocongress.esmo.org来源：ScienceLink · x.com